Market: Kubota-AUROLAB takes eyeMO to people in need around the world

Siriram says portable OCT is much-needed device for low-resource settings

Seattle’s Kubota Vision Inc, a clinical-stage specialty ophthalmology company of Kubota Pharmaceutical Holdings (Tokyo 4596), is providing AUROLAB of Madurai with an exclusive license for product development, manufacturing, and distribution of eyeMO.

An execution of a collaboration letter of intent between Kubota Vision and AUROLAB was announced on 6 Dec 2023.

AUROLAB intends to commercialize eyeMO in its core markets of India, Pakistan, Afghanistan, Bangladesh, Bhutan, Maldives, Nepal, and Sri Lanka, as well as select underserved markets in Asia, Africa, Latin America, and the Middle East.

Kuboto Vision Inc Chairman, President and CEO Roy Kubota said, “We are excited to accelerate our goal of bringing eyeMO to people in need around the world by partnering with AUROLAB, part of the Aravind Hospital Group. Aravind Hospital Group is the world’s largest eye hospital, performing 450,000 eye surgeries annually and distributing eye care equipment in over 160 countries worldwide.

“We believe that combining performance with cost-effectiveness is an important factor in promoting eyeMO in the global market. We will continue to develop and expand the applications of eyeMO to alert patients and their physicians of disease progression and re-treatment needs by facilitating at-home and in-office use in countries and regions where medical care is limited.”

AUROLAB MD R.D. Sriram added “We are happy to align with Kubota Vision in making the portable OCT a much-needed device for low-resource settings, especially when patients’ access to eye clinics is challenging.” Fiinews.com